PNC Financial Services Group
ELVN icon

PNC Financial Services Group’s Enliven Therapeutics ELVN Stock Holding History

PNC Financial Services Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Hold
22
– – ﹤0.01% 4819
2026
Q1 		$862 Hold
22
– – ﹤0.01% 4791
2025
Q4 		$339 Buy
22
+3
+16% +$60 ﹤0.01% 4918
2025
Q3 		$389 Buy
+19
New +$383 ﹤0.01% 4844
2024
Q2 		– Sell
-8
Closed -$141 – 4792
2024
Q1 		$141 Buy
8
+3
+60% +$46 ﹤0.01% 4631
2023
Q4 		$69 Buy
+5
New +$61 ﹤0.01% 4539

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

PNC Financial Services Group's ELVN Position: Q2 2026 in Review

PNC Financial Services Group held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 22 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4819.

PNC Financial Services Group first reported a position in ELVN in Q4 2023 and has held it in 6 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • PNC Financial Services Group held 22 shares of Enliven Therapeutics worth $1.12K as of Q2 2026.
  • PNC Financial Services Group left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4819 holding.
  • PNC Financial Services Group first reported a position in Enliven Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.